ReShape Lifesciences (RSLS) said Thursday it will implement a reduction in force that is expected to save more than $750,000 or about 23% of its annual payroll expenses.

Chief Executive Officer Paul Hickey said the company's sales and marketing team remains fully intact.

Hickey also said that the company is progressing towards finalizing the merger agreement with Vyome Therapeutics and the asset sale to Biorad Medisys, with a special shareholder meeting to vote on the transactions set for July 24.

Price: 2.47, Change: +0.01, Percent Change: +0.41